PDCD1 and melanoma: Accumulating data has demonstrated that simple complete blood count and general chemistry results may be informative with regard to therapeutic outcomes of advanced melanoma under the anti-PD-1 monotherapy (15–20), making them as promising collection of candidates for a potential biomarker panel development.